Autopsy report · NCT04779489
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
Cause of deathSlow enrollment
“Study was closed to low accrual.”
Life of this trial
- Registered 6 months before it started.
- Ran for about 1 year 9 months before it stopped.
- 1 participant enrolled.
- Results were posted on the registry 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- University of Texas Southwestern Medical Center
- Sponsor type
- University, hospital or other
- Conditions
- Bladder Cancer
- Interventions
- personalized ultrafractionated stereotactic ablative radiotherapy
- Participants
- 1
- Sites
- 1
- Countries
- United States
Trials that died the same way
- High Dose Rate Brachyablation of Primary Liver Lesions
“Study was closed due to poor accrual” - S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery
“This study was closed early due to poor accrual” - Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
“accrual was slow and sporadic so the study was closed” - Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
“The study was closed for slow accrual” - A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
“Study closed to enrollment due to low accrual.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.